Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (Nasdaq: CCCC) is a pioneering clinical-stage biopharmaceutical company focused on utilizing targeted protein degradation to create novel medicines that transform patient outcomes. The company's core technology, the TORPEDO® platform, enables the design and optimization of small-molecule medicines aimed at degrading disease-causing proteins through the ubiquitin/proteasome system. This innovative approach offers solutions to overcome drug resistance and target previously undruggable proteins.
C4 Therapeutics is actively advancing several proprietary oncology programs into clinical trials. Notable among these is CFT7455, also known as cemsidomide, an oral degrader targeting IKZF1/3 for treating relapsed/refractory multiple myeloma (R/R MM) and non-Hodgkin’s lymphomas (R/R NHL). Recent clinical data indicates that CFT7455 is well-tolerated and exhibits promising anti-myeloma activity, supporting its continued development.
Another key program, CFT1946, is an oral BiDAC™ degrader designed to target BRAF V600 mutations. This compound is being tested for its efficacy in treating solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma. Early clinical results are promising, showing that CFT1946 is active against BRAF V600E-driven disease and exhibits central nervous system (CNS) activity, a significant advantage over existing BRAF inhibitors.
In addition to its internal programs, C4 Therapeutics has established strategic partnerships with industry leaders such as Roche, Biogen, and Merck KGaA, Darmstadt, Germany. These collaborations aim to leverage the company's TORPEDO® platform to discover and develop new degraders targeting various oncogenic proteins. Notably, under an agreement with Merck KGaA, C4T will receive an upfront payment and significant milestone payments, underpinning the potential commercial success of their partnered programs.
Financially, C4 Therapeutics reported a total revenue of $20.8 million for 2023, with a net loss of $132.5 million. However, the company is well-capitalized, with cash, cash equivalents, and marketable securities amounting to $281.7 million as of December 31, 2023, ensuring sufficient funds to support its operations into 2027.
By continuously pushing the boundaries of targeted protein degradation science, C4 Therapeutics aims to revolutionize the treatment landscape for patients with challenging diseases, ultimately striving to deliver breakthrough therapies that significantly enhance patient care and outcomes.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in a fireside chat at the Stifel 2023 Virtual Targeted Oncology Days. The event is scheduled for April 26, 2023, at 11:00 AM ET. C4T is focused on advancing targeted protein degradation science to develop small-molecule medicines aimed at transforming disease treatment. Through its innovative TORPEDO® platform, C4T is designing therapies that leverage the body’s protein recycling system to degrade disease-causing proteins, addressing challenges like drug resistance. A live webcast of the chat will be available on C4T's website, along with an archived replay for 30 days post-event.
C4 Therapeutics (Nasdaq: CCCC) reported a revenue decline to $31.1 million for the year ended December 31, 2022, down from $45.8 million in 2021, primarily due to a one-time recognition in the prior year. R&D expenses increased to $117.8 million from $94.7 million, driven by clinical activities. The company posted a net loss of $128.2 million and net loss per share of $2.62, compared to $83.9 million and $1.82, respectively. Despite the financial challenges, C4T anticipates a cash runway until the end of 2024 and is focusing on advancing multiple clinical trials, with important data expected in 2H 2023.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a clinical-stage biopharmaceutical firm, announced its participation in two virtual conferences in February 2023. The SVB Securities Global Biopharma Conference will feature a fireside chat on February 15 at 3:00 PM ET, while a panel discussion titled Key Targets for Targeted Protein Degradation in Oncology is scheduled for February 21 at 12:00 PM ET during the 2023 Wells Fargo Targeted Protein Degradation Summit. Live webcasts will be accessible on the company’s website, with archived replays available for 30 days. C4T is focused on targeted protein degradation to develop innovative therapies for challenging diseases.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced the first patient has been dosed in its Phase 1/2 clinical trial for CFT1946, a targeted therapy for BRAF V600 mutant solid tumors. This marks the first degrader to enter clinical development aimed at BRAF-driven cancers, generally treated with limited options once resistance develops. Early studies indicate CFT1946 may offer deeper and more durable efficacy than current BRAF inhibitors. The trial will assess safety and effectiveness, progressing to evaluate CFT1946 both alone and with trametinib in advanced phases. This initiative expands C4T's oncology programs via its proprietary TORPEDO® platform.
C4 Therapeutics (Nasdaq: CCCC) reports continued progress in its oncology trials, with key updates expected in 2023. The company is advancing CFT7455 and CFT8634, focusing on multiple myeloma and synovial sarcoma treatments. Phase 1 dose escalation data for both drugs will be shared in the second half of 2023. Additionally, CFT1946 targeting BRAF-V600 mutations has initiated trials. As of September 30, 2022, C4T holds $366 million in cash, enough to fund operations into 2024. A presentation at the J.P. Morgan Healthcare Conference is also scheduled.
C4 Therapeutics (Nasdaq: CCCC), a clinical-stage biopharmaceutical company, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference on January 9, 2023, at 10:30 am PST (1:30 pm EST) in San Francisco. The event will be accessible via a live webcast on the company’s website, with a replay available for two weeks afterward. C4T focuses on targeted protein degradation to develop innovative medicines for difficult-to-treat diseases, leveraging its TORPEDO® platform to enhance patient outcomes.
C4 Therapeutics (Nasdaq: CCCC) reported a net loss of $32 million for Q3 2022 compared to $24.7 million in Q3 2021. Total revenue decreased to $6.8 million from $8.5 million, driven by collaborative agreements. R&D expenses rose to $29.7 million, primarily due to ongoing clinical trials for CFT7455 and CFT8634. They achieved IND clearance for CFT1946, a significant milestone expected to lead to Phase 1/2 trial initiation by year-end. Cash and marketable securities as of September 30, 2022, stood at $366 million, sufficient to fund operations until the end of 2024.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
What is the core technology of C4 Therapeutics?
What are the main focus areas of C4 Therapeutics’ current projects?
Who are some of C4 Therapeutics’ strategic partners?
What were C4 Therapeutics’ financial results for 2023?
What is CFT7455, also known as cemsidomide?
What is unique about CFT1946?
How does C4 Therapeutics’ technology address drug resistance?
What recent partnerships has C4 Therapeutics announced?
What are the cash and financial projections for C4 Therapeutics?
Where can I find more information about C4 Therapeutics' clinical trials?
